A True Breakthrough in Alzheimer's Disease
Noninvasive Neuromodulation: A True Breakthrough in Alzheimer's Disease
therapy for Alzheimer’s Disease that works by enhancing neuroplasticity via neurostimulation of key
brain networks involved in memory.
A Bold New Approach with
Unprecedented Clinical Trial Results
A Bold New Approach with Unprecedented Clinical Trial Results
Sinaptica’s scientific co-founders have published unprecedented Phase 2 placebo-controlled results that show our closed-loop neuromodulation therapy slows Alzheimer’s disease progression by >80% at 6 months, as measured by four different gold-standard cognitive & functional clinical trial endpoints.
Based on this unprecedented data, our mission is to advance this breakthrough into large-scale pivotal studies and get it to desperate patients—and their caregivers—as soon as possible.
The Default Mode Network (DMN) is a key brain network involved in episodic memory and implicated in Alzheimer’s Disease progression. Our highly personalized approach is calibrated for each individual based on precise measurements from MRI, TMS-Evoked potentials (TEPs), and other data, allowing us to individualize stimulation to achieve optimal response, safely.
Each patient’s brain is unique, and responds differently to neuromodulation. Our therapy uses neuronavigation to precisely and repeatably optimize electrical stimulation of the precuneus, which is the central hub of the DMN.
>80% disease slowing on four gold-standard
cognitive & functional endpoints
In a 50-patient randomized double-blind placebo controlled study, Sinaptica’s personalized rTMS-EEG neuromodulation was shown to profoundly preserve cognition and function after 6 months, compared to placebo. These results were published in the peer-reviewed Oxford University Press journal, Brain.
World-class Scientific Team
Giacomo Koch MD, PhD
Professor of Physiology, University of Ferrara.
Director, Brain Stimulation Laboratory, Santa Lucia Foundation.
Emiliano Santarnecchi PhD, PhD
Associate Professor at Harvard MGH. Director, Precision Neuroscience and Neuromodulation Program. Faculty at Harvard & MIT.